Figure 1
Strip electrocardiogram. Paroxysmal narrow QRS tachycardia with retrograde P waves, suggesting atrioventricular reentrant tachycardia, was converted to normal sinus rhythm with DC cardioversion.
TO THE EDITOR
Granulocyte transfusions are used to treat severe, progressive infections in patients with neutropenia despite use of appropriate antibiotic therapy and recombinant hematopoietic growth factors. 1, 2 However, several problems with granulocyte transfusion therapy still remain. 1, 2 Donors who receive recombinant human granulocyte colony-stimulating factor (G-CSF) experience mild bone pain, fatigue, headache, and sometimes a flu-like syndrome, which are readily relieved by analgesics. A small number of donors may also experience insomnia, restlessness, hypertension, hypocalcemia, edema, headache, pruritus, and dermatitis due to red cell sedimenting agents and the citrated anticoagulant used for filtration leukapheresis. During or after granulocyte transfusions, recipients have transfusion reactions, such as fever or chills, and are at risk of cytomegalovirus infection. In alloimmunized recipients, these toxic effects can also be associated with severe dyspnea, pulmonary infiltrates, and hypoxia, which may be fatal. However, no life-threatening cardiovascular complications associated with granulocyte transfusion have been described previously. This report describes a case of life-threatening paroxysmal supraventricular tachycardia (PSVT) during granulocyte transfusion that was successfully treated with electric cardioversion.
A 36-year-old man with acute myeloid leukemia (M6) relapsed after an initial complete remission that lasted 6 months. He was re-treated with idarubicin (12 mg/m 2 /day i.v. over 30 min on days 1-3) and N4-behenoyl-1-D-arabinofuranosylcytosine (300 mg/m 2 /day i.v. over 4 h on days 1-7) as part of the remission induction chemotherapy. There was no history of cardiac problems.
On the second day after chemotherapy, his neutrophils fell below 0.5 × 10 9 /l. Two days later, he developed a fever of 39.3°C, so G-CSF (5 g/kg) and empirical treatment with cefiramide sodium and amikacin was initiated. Over the next 3 days, a fever Ͼ38.5°C persisted and a chest X-ray showed pneumonic infiltrates in the right lower lung field. Vancomycin was added and the fever resolved. On day 13, a fever Ͼ39°C recurred, and the pulmonary infiltrates spread to the left lung field radiologically. Amphotericin B and intravenous immunoglobulin were added and the cefiramide sodium was replaced by imipenen/cilastatin. Cultures of blood, urine and sputum were sterile, and there was no evidence of alloimmunization, defined by unresponsiveness to platelet transfusions. However, his clinical condition continued to deteriorate and granulocyte transfusion therapy was planned on day 20.
The donor was given G-CSF 5 g/kg subcutaneously 12 h before leukapheresis and dexamethasone 3 mg/m 2 intravenously 15 min beforehand. Ten liters of centrifugal leukapheresis was performed with a Fenwall CS 3000 Plus blood cell separator at a flow rate of 50 ml/min, using 30 ml of sodium citrate solution (46.7% trisodium citrate) and 500 ml of 10% pentastarch. The concentration of granuloCorrespondence: J-J Lee; Fax: 82-62-2258578 Received 5 November 1999; accepted 14 March 2000 cytes collected (200 ml) was 15.5 × 10 10 /l, and the leukapheresis product was irradiated with 25 Gy before infusion into the patient.
After premedication with acetaminophen, pheniramine maleate and hydrocortisone, the granulocyte infusion was initiated slowly. Five minutes into the granulocyte transfusion, the patient complained of palpitations and dizziness. His blood pressure was 70/40 mmHg and an electrocardiogram (ECG) demonstrated a PSVT at a rate of 210 ( Figure 1 ). Pulse oxymetry monitored during the granulocyte transfusion did not show any hypoxemia, and he received continuous oxygen (4 l/min) by mask throughout the transfusion. The granulocyte transfusion was stopped immediately and two doses of adenosine (6-9 mg) were given, but the PSVT persisted. Subsequently, the PSVT was successfully restored to normal sinus rhythm with electric cardioversion (100 J) (Figure 1 ). An echocardiogram revealed no abnormalities and a follow-up ECG showed normal sinus rhythm. Over the next 2 weeks, the pulmonary infiltrates improved slowly, but unfortunately complete remission was not achieved.
Neutropenia-related infection is a major contributing factor to morbidity and mortality in patients with hematologic malignancy despite appropriate antibiotic therapy. Although granulocyte transfusion therapy was enthusiastically advocated in the 1970s and early 1980s, the use of granulocyte transfusion therapy has declined noticeably because of several problems associated with this therapy and the introduction of new antimicrobial agents and recombinant hematopoietic growth factors. 3 Recently, granulocyte transfusion therapy has received renewed interest, following several reports on the transfusion efficacy of granulocytes collected by stimulating normal donors with G-CSF.
3,4
To our knowledge, this is the first case of PSVT developing during granulocyte transfusion therapy in a patient with neutropenia-related infection. The reason for an arrhythmia associated with granulocyte transfusion therapy is not clear, but several possible factors should be contemplated, including the citrate anticoagulation solution, pentastarch, emotional stress, and transfusion reactions including hypoxemia. 5, 6 This report suggests that arrhythmia should be considered as a complication of granulocyte transfusion. ECG monitoring, as well as pulse oxymetry monitoring, may be needed during granulocyte transfusion therapy in patients with neutropenia-related infection.
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Department Allelic losses and genetic instabilities of PTEN and p73 in non-Hodgkin lymphomas Figure 1 Representative results of the LOH analysis at the p73 (a-c), and PTEN (d) loci. LOH, loss of heterozygosity; i, instability; L, lymphoma; N, normal sample; n, non-digested; d, digested. PCR amplifications were performed in a Perkin Elmer 2400 DNA thermal cycler (Norwalk, CT, USA), and the final products were resolved in 6% denaturing acrylamide 1 × TBE buffered gels. After electrophoresis, the DNA fragments were detected by silver staining. Amplifications corresponding to the StyI polymorphism were digested overnight and analyzed in 2% agarose gels stained with ethidium bromide.
TO THE EDITOR
Disruption of oncogenes and inactivation of tumor suppressor genes plays a central role in the pathogenesis of malignant disease. In leukemias and lymphomas, the detailed characterization of such abnormalities has provided a basis for disease classification, and has helped to define prognosis in individual patients. With regard to non-Hodgkin's lymphomas, little is known about the involvement of tumor suppressor genes with the exception of p53, and p16/INK4a/ARF, which . P73 is a new member of the p53 family that is frequently deleted in neuroblastoma and other human cancers.
5 Interestingly, transcriptional silencing of this gene in lymphoid malignancies due to hypermethylation of its 5Ј CpG island has been recently reported. 6 However, allelic losses were not detected in the cell lines exhibiting lack expression of this gene.
Here, we report an LOH study in 42 paired normal and primary NHLs samples of B and T cell lineage (Table 1) , using polymorphic DNA markers located into/or near PTEN and p73 loci. Lymphomas
